Inzucchi, S. E., Fitchett, D., Jurišić Eržen, D., Woo, V., Hantel, S., Janista, C. ... Zinman, B. (2020). Are the cardiovascular and kidney benefits of
empagliflozin influenced by baseline glucose‐
lowering therapy?. Diabetes, Obesity and Metabolism, 22. (4), 631-639. doi: 10.1111/dom.13938
Inzucchi, Silvio E., et al. "Are the cardiovascular and kidney benefits of
empagliflozin influenced by baseline glucose‐
lowering therapy?." Diabetes, Obesity and Metabolism, vol. 22, no. 4, 2020, pp. 631-639. https://doi.org/10.1111/dom.13938
Inzucchi, Silvio E., David Fitchett, Dubravka Jurišić Eržen, Vincent Woo, Stefan Hantel, Christina Janista, Stefan Kaspers, Jyothis T. George and Bernard... Zinman. "Are the cardiovascular and kidney benefits of
empagliflozin influenced by baseline glucose‐
lowering therapy?." Diabetes, Obesity and Metabolism 22, no. 4 (2020): 631-639. https://doi.org/10.1111/dom.13938
Inzucchi, S. E., et al. (2020) 'Are the cardiovascular and kidney benefits of
empagliflozin influenced by baseline glucose‐
lowering therapy?', Diabetes, Obesity and Metabolism, 22(4), pp. 631-639. doi: 10.1111/dom.13938
Inzucchi SE, Fitchett D, Jurišić Eržen D, Woo V, Hantel S, Janista C, and sur.. Are the cardiovascular and kidney benefits of
empagliflozin influenced by baseline glucose‐
lowering therapy?. Diabetes, Obesity and Metabolism [Internet]. 2020 [cited 2024 December 25];22(4):631-639. doi: 10.1111/dom.13938
S. E. Inzucchi, et al., "Are the cardiovascular and kidney benefits of
empagliflozin influenced by baseline glucose‐
lowering therapy?", Diabetes, Obesity and Metabolism, vol. 22, no. 4, pp. 631-639, 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:877245. [Accessed: 25 December 2024]